Introduction
Clinical resistance to antifungal agents was rare until the late 1980s, with only isolated cases in patients with chronic mucocutaneous candidiasis. 1, 2 The incidence of fungal infections, including resistant infections, has increased during the last 10 years, reflecting increased incidence of immunodeficiency associated with cancer chemotherapy, organ and bone marrow transplantation, and the HIV epidemic. 1, 3 Although the prevalence of drug resistance in fungi is below that observed in bacteria, many mycologists consider that selective pressure will, over time, lead to more widespread resistance. 1 There is considerable knowledge concerning the clinical, biochemical and genetic aspects of resistance to antifungal agents. 3, 4 However, sample selection and inadequate information regarding denominators limit current epidemiological data. At present, there is no established national surveillance scheme to identify changes in antifungal susceptibility that are clearly linked to over-the-counter (OTC) use. In addition, there are no large-scale epidemiological surveys of the extent of antifungal drug resistance in the published world literature.
Legal basis of classification in the UK
The supply of medicinal products varies internationally. In the UK there are three categories for the sale or supply of medicines to the public: prescription-only medicines (POM), pharmacy medicines (P), which can only be sold under the supervision of a pharmacist in a pharmacy, and general sales list medicines (GSL), which can be sold from any lockable shop. 5, 6 P and GSL medicines may be promoted to the public.
The recent regulatory atmosphere in the UK has been positive towards deregulation, as it encourages greater flexibility in access to healthcare, may reduce general practitioner (GP) consultation rates for minor illness and the cost to the National Health Service, (NHS) and encourages development of the professional role of the pharmacist.
Antifungal agents available without prescription in the UK
In the UK there is one antifungal agent for systemic administration (oral fluconazole) and numerous antifungal agents for topical administration authorized as P and GSL medicines (Table 1) . Antifungal agents approved as P products include creams, lotions, shampoos and sprays for the topical treatment of tinea (tinea capitis, tinea corporis, tinea cruris, tinea pedis, tinea versicolor), agents for candidal skin and vaginal infections, and clotrimazole solution for fungal infection in otitis externa. The only systemic antifungal agent currently available as a P medicine for systemic use is fluconazole (as a single-dose oral formulation) for the treatment of vaginal candidosis and candidal balanitis. Ketoconazole and terbinafine, which are used as systemic and topical medications, are available without prescription for topical use only. Nystatin in combination with hydrocortisone 0.5% is available without prescription as a P medicine for topical use in the UK; a new liposomal intravenous nystatin preparation is available but has not yet been licensed in the UK. If licensed, liposomal nystatin would not be available except as a POM.
Definition and mechanisms of fungal resistance
In 1997, the NCCLS proposed methods and guidelines for antifungal resistance testing of yeasts. 7 The NCCLS breakpoints include susceptible, susceptible dose-dependent and resistant categories based on in vitro and clinical data. The NCCLS document M38-P proposes methods and guidelines for resistance testing of filamentous fungi. There is currently no susceptibility standard for dermatophytes.
It is recognized that there is a gulf between the information derived in vitro, and the paucity of information regarding clinical risk. 8 In vitro demonstration of resistance does not necessarily equate to in vivo resistance. Other determinants in the selection of resistance include host-related factors, e.g. immunosuppression, the site and severity of A summary of mechanisms for the different antifungal classes where agents are currently available without prescription in the UK is shown in Table 2 .
Controlling resistance
The primary factor driving the emergence of antifungal resistance appears to be selective pressure resulting from the increased use and inappropriate prescribing of systemic antifungal agents. 9 The opinion has been expressed that owing to the serious nature of many systemic fungal infections and the difficulty with isolation and identification of some fungal pathogens efforts to counter resistance should focus on the following: 9, 10 • Delaying the initiation of systemic azole therapy.
• Optimizing therapy according to pharmacokinetic and pharmacodynamic properties and thus reducing exposure to low concentrations of systemic agents. There is no clear evidence as to what dosing strategy should be used during treatment and prophylaxis to best avoid resistance. 3 Experience with other anti-infective agents has led to predictions that continuous treatment with a high dose of drug for as brief a time as is possible to effect cure would result in the least risk, but this needs evaluation in clinical trials.
• Use of combination antifungal therapy may be more effective in preventing development of resistance. The combination of amphotericin and flucytosine is currently in use; amphotericin and azoles, azoles and flucytosine, and azoles and terbinafine are being tested.
• Use of adjunctive immunostimulatory therapy, e.g. azoles and cytokines.
• Use of azoles and efflux pump inhibitors.
• Avoidance of prophylactic use of azoles for oral or vaginal candidiasis.
Complementary suggestions include the following:
• Substitution of topical agents for systemic antifungals when appropriate, e.g. in infections of the mucous membranes, skin and bladder. It is considered that by reducing the use of systemic antifungal agents exposure of the host flora to the antifungal agent would be minimized, infections caused by fungi often occurring when host flora has been altered.
• Avoidance of unnecessary use of antibiotics that may affect the host flora (antibiotic effects on the host flora are recognized to be more frequent than antifungal effects).
• Avoidance of therapeutic regimens prone to cause crossresistance to amphotericin. 
Potential impact of increasing the availability of OTC antifungal agents
The potential for increased risk of development of bacterial resistance in the community is considered an 'indirect danger to health' and is assessed in every application for reclassification of an antimicrobial agent. 5, 6 It is recognized that there is an established but complex relation between the consumption of antimicrobial agents and the prevalence of drug resistance in microorganisms. It is also recognized that exposure to a given medicinal agent will usually increase with non-prescription availability. Total utilization of systemic azole antifungal agents has been implicated in the emergence of resistant Candida species at some institutions. However, other institutions with similar usage patterns have reported a declining incidence of isolation of resistant species. 3, 9, 11, 12 The availability of oral fluconazole for treatment of vaginal candidal infection and more recently for candidal balanitis, and of nystatin combined with 1% hydrocortisone for topical application, is associated with new potential risks to the public. Both fluconazole and nystatin are members of crucially important families of antifungal drugs. There have been increasing reports of resistance to the azoles in hospitalized patients during the 1990s. 11, 12 Although reports of nystatin resistance are rare, 13 if crossresistance to amphotericin were to become prevalent, the outlook for patients with systemic fungal infections would be unfavourable.
However, there is very little robust evidence that nonprescription use of topical antifungal agents has been associated with the emergence of resistance. 9 Although azoles are associated with cross-resistance, which has a negative impact on their use for systemic life-threatening infections, there is insufficient evidence that the use of topical azoles (e.g. in cream, shampoo, powders or in washing machine detergents) and/or OTC use has been associated with the emergence of resistance or cross-resistance. The resistances of clinical importance are felt to be cryptococcal and candidal resistance. The emergence of resistant Candida species has also coincided with a background of generally increased candidal isolation rates and increased institutional use of azoles. Institutions with similar azole usage patterns have reported increasing or declining incidence of isolation of resistant species. 3, 9, 11, 12 It is also important to note that development of resistance during courses of therapy lasting less than several weeks has not been widely reported. In evidence given to the House of Lords Select Committee, reference was made to the uncontrolled OTC availability of fluconazole in Spain and Greece and that there were concerns with regard to azole resistance, in particular with the emergence of Candida glabrata, in these countries (no further details were given).
14 There have also been more reports of C. glabrata, from vaginal isolates in the UK, the significance of which is uncertain (PHLS, personal communication). In the UK the only antifungal agent available for systemic use without prescription is only available as a single capsule from pharmacies. It is currently unclear as to whether more-regulated use would cause a reduction in the current prevalence of resistance at an institutional or at a community level.
It is recognized that there is poor compliance with use of topical agents for superficial fungal infections of the skin as symptoms are rapidly relieved whether or not there has been mycological cure. 15 It has also been postulated that the treatment period with topical agents for presumptive vulvo-vaginal candidiasis is too short and may contribute to subclinical candidal infection. 16 Use of the same agents under the supervision of a physician may improve the situation. However, there is no clear evidence to support this.
There is no robust evidence that restricting the use of OTC antifungal medicines currently available in the UK will reverse or arrest the present situation. At present, there is no national systemic monitoring arrangement prospectively studying trends in antifungal resistance in the UK in order to produce such information. 17 Current data are selective in terms of sampling and are almost all derived from a small percentage of patients from intensive care and oncology facilities, and cannot be extrapolated to the community. The data are also rarely denominator controlled. Currently there is no established national surveillance scheme that would be sufficiently sensitive to identify changes in susceptibility that are clearly linked to OTC use, and no agreed level of in vitro resistance accepted by any licensing authorities that would automatically result in a recommendation that a licence should be modified or withdrawn for a particular drug. Industry, government and clinicians should be responsible for establishing a scheme for national surveillance. This should provide accurate information on resistant strains in hospitals and the community, and the clinical outcomes associated with these strains. It may be that by restricting the non-prescription availability of future agents, a problem that has not yet evolved could be prevented and the future efficacy of new chemically related antifungal agents, if subsequently authorized in the UK, would be enhanced. It is also possible that the 'local immunosuppression' caused by the combination of a mild steroid with many of the topical agents could further encourage the growth of resistant fungi that may be present on initiation of therapy or that may emerge during treatment. Preparations of the same antifungal agent that do not include a steroid may be less favourable to the growth of resistant organisms.
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The current situation does not permit assurance that undesirable resistance problems may not occur in the future. There have already been fungal pathogens isolated in the UK that are resistant in vitro to all currently available antifungal agents, e.g. Scedosporium prolificans, and there have been numerous reports of this same pathogen from Spain. 17, 18 Some agents have not been available for a sufficiently long period and others have been applied topically to superficial mycoses but not to deep mycoses.
With deregulation, the sales of antifungal agents will increase; in the USA since the lifting of the POM status for local antimycotics against vulvo-vaginal candidiasis there has been a doubling of sales. 19 The OTC European antifungal market is expected to grow by almost 12% between 1998 and 2003 and the OTC gynaecological antifungal market by 15%. 20 This follows a 32% growth in the UK market for antifungal self-medication between 1993 and 1998 and a 230% growth in the UK gynaecological market for antifungal self-medication between 1993 and 1998. 20 Thus the primary factor driving the emergence of antifungal resistance, namely selective pressure from increased use and inappropriate use will increase. However, with the exception of oral fluconazole these are topically administered agents for which the risks from such use are deemed to be lower.
Other potential contributions to antifungal resistance
Since the 1970s the resistance of phytopathogenic fungi to fungicides has been causing serious problems in crop production. Fungicide use is generally limited to fruit and vegetable crops, and for seed and lawn treatments. Apples and potatoes account for approximately 26% of all fungicides used in agriculture, with about 97% of potato hectarage treated with fungicides. 21 Pyridine and pyrimidine antifungal agents used exclusively and very extensively in agriculture have a very similar mechanism of action to the azoles, 22 and it is possible that such use could have contributed to the emergence of azole resistance. Imidazole and triazole derivatives have been marketed for use in both agriculture and medicine. It is difficult to ascertain measures of human exposure to these agents because of their widespread distribution and limited information concerning effects of human exposure in the published literature. The residues in a crop may be less or more toxic than the parent compound and the effect on resistance of human pathogenic fungi is unknown.
Biocides are agents with antiseptic, disinfectant and/ or preservative properties and are used extensively in cleaning agents and for human use. Comparatively little information exists about antifungal mechanisms of these agents. However, the concentrations required to inhibit growth are often very much lower than fungicidal concentrations. Possible mechanisms of resistance may involve plasmid-mediated transfer, which could potentially contribute to rapid spread. 9, 23 Comparative studies on the drug resistance of the different classes of antifungal agents against various fungi pathogenic for man, animals and plants may be useful.
Conclusion
Although extremely rare 10 years ago, antifungal drug resistance has become a problem. It is, however, restricted to certain populations in specific clinical settings. The level of fungal drug resistance is below that observed for bacteria.
The increased use of antifungal agents will lead to increased selective pressure and a theoretical risk of resistance. However, there is very little robust evidence that non-prescription use of topical antifungal agents or of fluconazole as a single tablet has been associated with the emergence of resistance. In addition, there is no established national surveillance scheme that is sufficiently sensitive to identify changes in susceptibility that might be clearly linked to OTC use. However, future proposals for extension in the duration of use of topical OTC antifungal agents or proposals for OTC availability of antifungal medications for systemic use would need careful consideration with respect to the possibility of selecting for resistance. National surveillance data on resistance in hospitals and the community would also be required. Further consideration should be given to the possible contribution of agricultural fungicides to the emergence of azole resistance.
The massive prevalence of fungal dermatological and gynaecological infections, which are usually minor and for which at least moderately effective and very safe topical treatments have been available over the counter for many years, dictates that such treatments should usually remain available at such outlets. However, should patterns of resistance change in the future this position may need to be further reviewed.
